Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(13):1050-1051; doi:10.1093/jnci/djm014
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/13/1050-a    most recent
djm014v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Clavarezza, M.
Right arrow Articles by Venturini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clavarezza, M.
Right arrow Articles by Venturini, M.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy

Matteo Clavarezza, Lucia Del Mastro, Paolo Pronzato, Paolo Bruzzi, Marco Venturini

Affiliations of authors: Department of Medical Oncology (MC, LDM, PP), and Clinical Epidemiology (PB), National Cancer Research Institute, Genoa, Italy; Department of Medical Oncology, Negrar Hospital, Verona, Italy (MV)

Correspondence to: Matteo Clavarezza, MD, Department of Medical Oncology, National Cancer Research Institute, L.go Rosanna Benzi, n.10 16132, Genoa, Italy (e-mail: matteo.clavarezza@istge.it).

The first 10% of the full text of this article appears below.

Hershman et al. (1) reported an increased risk (hazard ratio [HR] = 2.14) of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) among women with breast cancer aged 65 years or older included in the Surveillance, Epidemiology, and End Results (SEER)—Medicare database who were treated with adjuvant chemotherapy and received granulocyte colony-stimulating factors (G-CSFs) or granulocyte–macrophage colony-stimulating factors . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

Response: Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
Dawn Hershman, Alfred I. Neugut, and Victor Grann
J Natl Cancer Inst 2007 99: 1051-1052. [Extract] [Full Text] [PDF]